Over the last 12 months, CG Oncology insiders reported 1 buy totaling $24.8M and 6 sales totaling $2.7M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | POST LEONARD ED | ▼ Sale | 1,000 | $71.17 | $71K | -100% | plan |
| Jul 10, 2026 | Mulay JamesD | ▼ Sale | 24,165 | $75.16 | $1.8M | -100% | plan |
| Jun 25, 2026 | Liu Brian Guan-ChyunD | ▲ Buy | 371,085 | $66.87 | $24.8M | +24.5% | plan · indirect |
| Jun 24, 2026 | POST LEONARD ED | ▼ Sale | 5,000 | $70 | $350K | -100% | plan |
| Jun 22, 2026 | POST LEONARD ED | ▼ Sale | 5,000 | $65 | $325K | -100% | plan |
| Jun 15, 2026 | Mulay JamesD | ▼ Sale | 1,964 | $60.12 | $118K | -100% | plan · 2 tranches |
| Jun 4, 2026 | POST LEONARD ED | ▼ Sale | 1,000 | $54.5 | $55K | -100% | plan |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CGON feed.